Milestone Pharmaceuticals Inc.

NASDAQ:MIST

Biotechnology

Healthcare
$0.41 -0.01%

-$0.00 today

Market cap
$51.44M
Beta
0.96
P/E (TTM)
-2.5
EPS (TTM)
-$0.52
52W Low $1.00High $3.06

Volume 5.54M

Average 1.99M

MIST EBITDA Margin

EBITDA as a percentage of revenue.

Milestone Pharmaceuticals Inc.NASDAQ: MIST

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin at -9237.0%

EBITDA Margin was -9237.0% in Q1 FY2026. On a trailing-twelve-month basis it was -3439.7%. Over 3 fiscal years it narrowed by 2679.5 pp.

Context

  • EBITDA Margin widened in 1 of the last 2 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 5 analysts of -1328.3% for the fiscal year ending Dec 2026, up from -3845.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-9237.0%-8176.8 pp QoQ
Last fiscal yearDec 2025
-3845.5%— YoY
LTMMar 2026
-3439.7%— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year—+2517.2 pp—
3 years-2679.5 pp+3795.4 pp+6474.9 pp
5 years+3858.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-3845.5%
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How MIST compares with its peers on the latest reported figures

  • MIST's LTM Mar 2026 EBITDA Margin of -3439.7% is the 3rd highest of the 4 companies compared; the peer median is -1566.1%.
  • Over three fiscal years its change of -2679.5 pp compares with a peer median of +420.7 pp.
MIST Competitors Peer median
EBITDA Margin for MIST and competitors
Company Period LTM level YoY 3-year change
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026-1053.3% +3016.0 pp—
IPHAInnate Pharma S.A.FY2025-1566.1% -1194.4 pp-1544.8 pp
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-3439.7% —-2679.5 pp
CRDFCardiff Oncology, Inc.LTM Mar 2026-8329.5% -111.2 pp+2386.2 pp
PEPGPepGen Inc.FY2025— ——
MOLNMolecular Partners AGFY2025— ——
CRBPCorbus Pharmaceuticals Holdings, Inc.FY2025— ——
ELTXElicio Therapeutics, Inc.FY2025— ——
Peer median (excluding MIST) -1566.1%-111.2 pp+420.7 pp

Competitors are the stored peer set for MIST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue15M5M1M01.55M
Cost of Revenue0000114K
Gross Profit15M5M1M01.43M
Gross Margin100.0%100.0%100.0%—92.6%
Research & Development38.67M39.83M31.05M14.36M18.11M
Selling, General & Admin19.4M24.81M31.05M27.75M17.27M
Operating Expenses58.07M64.64M62.1M42.1M63.92M
Depreciation & Amortization93K89K92K105K114K
EBITDA(42.76M)(58.3M)(57.04M)(37.83M)(59.45M)
EBITDA Margin-285.1%-1166.0%-5703.9%—-3845.5%
Operating Income(43.07M)(59.64M)(61.1M)(42.1M)(62.49M)
Operating Margin-287.2%-1192.8%-6109.8%—-4041.7%
Interest Income220K1.25M3.97M4.16M2.92M
Interest Expense002.55M(3.58M)3.84M
Other Income / Expenses220K1.25M1.41M583K(918K)
Income Before Tax(42.85M)(58.39M)(59.69M)(41.52M)(63.4M)
Pre-Tax Margin-285.7%-1167.8%-5968.5%—-4101.1%
Income Tax Expense0000(345K)
Net Income(42.85M)(58.39M)(59.69M)(41.52M)(63.06M)
Net Margin-285.7%-1167.8%-5968.5%—-4078.8%
EPS (Basic)(1.02)(1.35)(1.39)(0.67)(0.75)
EPS (Diluted)(1.02)(1.35)(1.39)(0.67)(0.75)
Weighted Avg Shares41.83M42.45M42.96M62.21M83.88M
Weighted Avg Shares (Diluted)41.83M42.45M42.96M62.21M83.88M

Milestone Pharmaceuticals Inc.

NASDAQ:MIST

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.